HUM vs NVS
Humana vs Novartis AG — AI-powered side-by-side comparison
| Metric | HUM | NVS |
|---|
| AI Score |
68
|
72
|
| Price |
$389.25
|
$150.91
|
| P/E Ratio |
36.53×
|
22.85×
|
| ROE |
6.7%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
13.7%
|
74.3%
|
| Debt / Equity |
0.74×
|
1.18×
|
| Dividend Yield |
0.9%
|
3.0%
|
| RSI (14) |
58.2
|
32.8
|
| Beta |
0.74
|
0.462
|
| Expected Upside |
+9.8%
|
+3.5%
|
AI Committee View
Current Innellis committee reasoning for HUM versus NVS.
NVS leads by 4 points.
NVS scores 72/100 (Buy) versus HUM at 68/100 (Buy).
HUM Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
NVS Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.56 across 9 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical